Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

20082,177 citationsJournal Article

Authors

Johann S. de Bono · Royal Marsden Hospital

Howard I. Scher · Memorial Sloan Kettering Cancer Center

Bruce Montgomery · University of Washington

Christopher Parker · Royal Marsden Hospital

Michael Craig Miller · Eon Corporation (United States)

H. Tissing · Eon Corporation (United States)

Gerald V. Doyle

Abstract

CTC are the most accurate and independent predictor of OS in CRPC. These data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.

Topics & Keywords

Cancer Cells and Metastasis Prostate Cancer Treatment and Research Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 14, Issue 19, pp. 6302-6309

DOI: 10.1158/1078-0432.ccr-08-0872

Field-Weighted Citation Impact: 36.40